Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis

References

• Thorne JE, Suhler E, Skup M, et al. Prevalence of noninfectious uveitis in the united states: A claims-based analysis. JAMA Ophthalmol. 2016;134(11):1237–1245. doi:10.1001/jamaophthalmol.2016.3229.
   PubMed Web of Science ®Google Scholar
• De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87(7):879–884. doi:10.1136/bjo.87.7.879.
   PubMed Web of Science ®Google Scholar
• Henderson LA, Zurakowski D, Angeles-Han ST, et al. Medication use in juvenile uveitis patients enrolled in the childhood arthritis and rheumatology research alliance registry. Pediatr Rheumatol Online J. 2016;14(1):9. doi:10.1186/s12969-016-0069-5.
   PubMedGoogle Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merril PT, Jaffe GJ, et al. Adalimumab for prevention of uveitis flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087. doi:10.1016/j.ophtha.2017.12.039.
   PubMed Web of Science ®Google Scholar
• Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45(8):1167–1172. doi:10.3899/jrheum.171006.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646. doi:10.1056/NEJMoa1614160.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39(6):1294–1295. doi:10.3899/jrheum.120010.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Mesquida AA, Anton J, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183–2188. doi:10.3899/jrheum.160231.
   PubMed Web of Science ®Google Scholar
• Calvio-Río V, Santo-Gómez M, Calvo I, et al. Anti-interleukine-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy. A multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69(3):668–675. doi:10.1002/art.39940.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkan I, Herbort CP, Khairallah M. Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539–592. doi:10.1007/s10792-008-9263-x.
   PubMedGoogle Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80. doi:10.1016/j.ajo.2017.08.019.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–6. doi:10.1111/aos.13015.
   PubMed Web of Science ®Google Scholar
• Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632. doi:10.1007/s00417-013-2436-y.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et.al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380–2386. doi:10.1016/j.ophtha.2014.06.050.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S75–9.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;25(2):215–220. doi:10.3109/09273948.2015.1099680.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, de la Hera D, Beltrán-Catalán E, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S54–7.
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-il6-r tocilizumab in refractory and non-infectious uveitic cystoid macular edema. Multicenter study of 25 patients. Am J Ophthalmol. 2019;S002-9394(19):30003.
   Google Scholar
• Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428–437. doi:10.1016/j.ophtha.2018.09.044.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. An Rheum Dis. 2015;74(6):1110–1117. doi:10.1136/annrheumdis-2014-205351.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395. doi:10.1056/NEJMoa1112802.
   PubMed Web of Science ®Google Scholar